Clinical Pharmacokinetics

, Volume 34, Issue 6, pp 421–428

Clinical Pharmacokinetics of Lornoxicam

A Short Half-life Oxicam
Review Article Drug Disposition

Summary

Lornoxicam (chlorotenoxicam) is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class. Unlike other oxicams, lornoxicam has a relatively short plasma half-life (3 to 5 hours). Lornoxicam is eliminated following biotransformation to 5′-hydroxy-lornoxicam, which does not undergo enterohepatic recirculation. Glucoroconjugated metabolites are excreted in urine and faeces with a half-life of about 11 hours.

Lornoxicam and its metabolites bind extensively to plasma albumin. Substantial concentrations of lornoxicam are attained in synovial fluid, the proposed site of action in chronic inflammatory arthropathies. The effects of lornoxicam concentration on its therapeutic and toxicological properties have not yet been extensively reported. Lornoxicam, like other NSAIDs, appears to interact with warfarin, sulphonylureas, digoxin and furosemide.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Balfour JA, Fitton A, Barradell LB. Lornoxicam: a review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs 1996; 51 (4): 639–57.PubMedCrossRefGoogle Scholar
  2. 2.
    Pruss TP, Stroissnig H, Radhofer-Welte S, et al. Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam. Postgrad Med J 1990; 66 Suppl. 4: S18–21.Google Scholar
  3. 3.
    Stiernieri E, Bussone G, Manzoni GC. Lornoxicam, a new nonsteroidal anti-inflammatory drug, in migraine prophylaxis: double-blind multicenter study. Cephalalgia 1991; 11 Suppl. 11: 154–5.Google Scholar
  4. 4.
    Dittrich P, Ferber HP, Kukovetz WR. Determination of chlortenoxicam, a novel nonsteroidal anti-inflammatory drug in human plasma [abstract P573]. 10th International Congress of Pharmacology: 1987 Aug 23–8; Sydney.Google Scholar
  5. 5.
    Suwa T, Urano H, Shinohara Y, et al. Simultaneous high-performance liquid Chromatographic determination of lornoxicam and its 5′-hydroxy metabolite in human plasma using electrochemical detection. J Chromatogr B Biomed Appl 1993; 617: 105–10.CrossRefGoogle Scholar
  6. 6.
    Hitzenberger G, Radhofer-Welte S, Takacs F, et al. Pharmacokinetics of lornoxicam in man. Postgrad Med J 1990; 66 Suppl. 4: S2–6.Google Scholar
  7. 7.
    Ankier SI, Brimelow AE, Crome P, et al. Chlortenoxicam pharmacokinetics in young and elderly human volunteers. Postgrad Med J 1988; 64: 752–4.PubMedCrossRefGoogle Scholar
  8. 8.
    Dittrich P, Radhofer-Welte S, Mayerhofer S, et al. Comparative pharmacokinetics of parenteral lornoxicam [abstract]. Eur J Pharmacol 1990; 183: 2265–6.CrossRefGoogle Scholar
  9. 9.
    Ravic M, Johnston A, Turner P. Clinical pharmacological studies of some possible Interactions of lornoxicam with other drugs. Postgrad Med J 1990; 66: Suppl. 4: S30–4.PubMedGoogle Scholar
  10. 10.
    Turner P, Johnston A. Clinical pharmacokinetic studies with lornoxicam. Postgrad Med J 1990; 66 Suppl. 4: S28–9.Google Scholar
  11. 11.
    Ravic M, Johnston A, Turner P, et al. The effect of repeated oral doses of lornoxicam on antipyrine elimination in normal human volunteers. Hum Exp Toxicol 1991; 10: 375–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Ravic M, Johnston A, Turner P, et al. Does bismuth chelate influence lornoxicam absorption? [letter]. Hum Exp Toxicol 1992; 11: 59–60.PubMedCrossRefGoogle Scholar
  13. 13.
    Ravic M, Salas-Herrera I, Johnston A, et al. Influence of lornoxicam a new non-steroidal anti-inflammatory drug on lithium pharmacokinetics. Hum Psychopharm 1993; 8: 289–92.CrossRefGoogle Scholar
  14. 14.
    Ravic M, Salas-Herrera I, Johnston A, et al. A pharmacokinetic interaction between cimetidine or ranitidine and lornoxicam. Postgrad Med J 1993; 69: 865–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Dittrich P, Radhofer-Welte S, Magometschnigg D, et al. The effect of concomitantly administered antacids on the bioavailability of lornoxicam, a novel highly potent NSAID. Drys Exp Clin Res 1990; 16 (2): 57–62.Google Scholar
  16. 16.
    Mayerhofer S, Welte S, Magometschnigg D, et al. The effect of food on pharmacokinetic parameters of the new NSAID lornoxicam in healthy volunteers [abstract]. 3rd Interscience World Conference on Inflammation, Antirheumatics, Analgesics and Immunimodulators: 1989 Mar 15–8; Monte Carlo.Google Scholar
  17. 17.
    Bareggi SR, Gambaro V, Valenti M, et al. Absorption of oral lornoxicam in healthy volunteers using a granular formulation in comparison with standard tablets. Arzneimettel Forschung 1997; 47 (1): 755–7.Google Scholar
  18. 18.
    Olkkola KT, Brunetto AV, Matilla MJ. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clin Pharmacokinet 1994; 26: 107–20.PubMedCrossRefGoogle Scholar
  19. 19.
    Albengres W, Urien S, Barre J, et al. Clinical pharmacology of oxicams: new insights into the mechanisms of their dosedependent toxicity. Int J Tissue React 1993; 15 (3): 125–34.PubMedGoogle Scholar
  20. 20.
    Leeman TD, Transon C, Bonnabry P, et al. A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. Drugs Exp Clin Res 1993; 19: 189–95.Google Scholar
  21. 21.
    Bonnabry P, Leeman T, Dayer P. Role of human liver cytochrome cytochrome P450TB (CYP2C subfamily) in the biotransformation of lornoxicam. Clin Pharmacol Ther 1996; 49: 305–8.Google Scholar
  22. 22.
    Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac: therapeutic insights and pitfalls. Clin Pharmacokinet 1997; 33 (3): 184–213.PubMedCrossRefGoogle Scholar
  23. 23.
    Reuter BK, Davies NM, Wallace JL. NSAID-enteropathy in rats: role of epithelial permeability, bacterial load, and enterohepatic circulation. Gastroenterology 1997; 112 (1): 109–17.PubMedCrossRefGoogle Scholar
  24. 24.
    Ravic M, Johnston A, Turner P, et al. A study of the interaction between lornoxicam and warfarin in healthy volunteers. Hum Exp Toxicol 1990; 9: 413–4.PubMedCrossRefGoogle Scholar
  25. 25.
    Hitoglou-Makedou A, Lawson M, Turner P, et al. Comparison of chlortenoxicam and indomethacin on furosemide-induced diuresis. Postgrad Med J 1989; 65: 821–3.PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1998

Authors and Affiliations

  1. 1.Department of MedicineUniversity of CalgaryCalgaryCanada
  2. 2.Department of Pharmacology and Therapeutics, Intestinal Disease Research Unit, Faculty of MedicineUniversity of CalgaryCalgaryCanada

Personalised recommendations